Geneva, Switzerland (PRWEB) January 16, 2013
Selexis SA announced today data from the Company’s SUREtechnology Platform™ will be presented at the 12th Annual PepTalk Conference, January 21-25, 2013 at the Renaissance Hotel & Palm Springs Convention Center in Palm Springs, California.
Selexis’ CEO, Igor Fisch, Ph.D., will present, “SURE CHO-M plus – Selexis’ Next Generation Cell Lines for Overcoming Expression Bottlenecks,” on Thursday, January 24 at 9:50 AM as part of the Pipeline 4: Expression - ‘Fine-Tuning Expression in CHO’ tract.
With certain proteins, optimal productivity cannot be achieved solely by elevated transcription. The secretory pathway needs to be modified to adjust for the increased load. The Selexis SURE CHO-M plus™ panel of modified cell lines addresses different secretory bottlenecks and provides a powerful tool for optimizing expression of difficult-to-express proteins.
Additionally, Zymeworks’ Director of External R&D and Alliances, David Poon, Ph.D., will present, “Bispecific Antibodies From a Novel Stable Expression Platform – Case Study: Development of an Azymetric™ Antibody Using the Selexis SUREtechnology Platform™,” on Friday, January 25 at 9:50 AM as part of the Pipeline 3: Biotherapeutics - ‘Bispecific Antibody Therapeutics’ tract.
The Zymeworks Azymetric™ platform is an IgG1-based bispecific antibody formed by assembly of engineered heterodimeric heavy chains. Stable, high-expressing CHO clones of an Az
Copyright©2012 Vocus, Inc.
All rights reserved